Jeff Sharman, MD: MRD testing at this point is prognostic; it tells you how likely a patient is to maintain their response. But to date, there’s nothing that tells us how to change therapy based on MRD status. There are studies coming that will potentially have MRD-adapted treatment decisions. Findings from those studies have not reported. MRD testing, therefore, really just helps us to understand the likelihood of length of a response.
With patients treated with BTK strategies, MRD isn’t so much a consideration. That’s primary amongst patients treated with venetoclax. We’re asked how accurately it predicts the risk of relapse and how widely is it being used. Well, again, following obinutuzumab-venetoclax, you can check MRD status. From the MURANO Study, which is a population of relapsed-refractory patients treated with obinutuzumab-venetoclax, you can stratify based upon MRD high, low, and negative. If you’re negative, chances are you’re going to maintain your response considerably longer than those patients who are low or high. Those patients are going to have relatively short durations of response.
Transcript edited for clarity.
Case: A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia
Initial presentation
Clinical workup
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More